186 related articles for article (PubMed ID: 36074319)
1. Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.
Hui VW; Au CL; Lam ASM; Yip TC; Tse YK; Lai JC; Chan HL; Wong VW; Wong GL
Hepatol Int; 2022 Dec; 16(6):1318-1329. PubMed ID: 36074319
[TBL] [Abstract][Full Text] [Related]
2. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML
Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251
[TBL] [Abstract][Full Text] [Related]
3. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
[TBL] [Abstract][Full Text] [Related]
4. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
[TBL] [Abstract][Full Text] [Related]
5. Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.
Kaya M; Nakamura K; Sugiyama K; Kinae A; Yamaguchi H; Ukita H; Odagiri K; Ujiie C; Kato J; Kageyama F; Nagura M; Matsushita K; Sugiue K; Ishida H; Endo S; Suzuki T
J Clin Pharm Ther; 2022 Jul; 47(7):940-947. PubMed ID: 35229326
[TBL] [Abstract][Full Text] [Related]
6. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.
Gao LH; Nie QH; Zhao XT
Int J Gen Med; 2021; 14():289-301. PubMed ID: 33536776
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study.
Curry MP; Flamm SL; Milligan S; Tsai N; Wick N; Younossi Z; Afdhal NH
J Manag Care Spec Pharm; 2021 Sep; 27(9):1239-1248. PubMed ID: 34105360
[No Abstract] [Full Text] [Related]
8. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
[TBL] [Abstract][Full Text] [Related]
9. Identification and management of contraindicated drug-drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy.
Kuo MH; Tseng CW; Lee CH; Yang YC; Wu HJ; Lin HJ; Chu YL; Chen YC; Tseng KC
J Formos Med Assoc; 2022 Jan; 121(1 Pt 1):58-65. PubMed ID: 33518448
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
Sicras Mainar A; Navarro Artieda R; Hernández I; Morillo R
Gastroenterol Hepatol; 2019 Oct; 42(8):465-475. PubMed ID: 31451229
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.
Sun HY; Cheng CY; Lin CY; Yang CJ; Lee NY; Liou BH; Tang HJ; Liu YM; Lee CY; Chen TC; Huang YC; Lee YT; Tsai MJ; Lu PL; Tsai HC; Wang NC; Hung TC; Cheng SH; Hung CC
World J Gastroenterol; 2022 Mar; 28(11):1172-1183. PubMed ID: 35431505
[TBL] [Abstract][Full Text] [Related]
12. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
Garrison KL; German P; Mogalian E; Mathias A
Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
[TBL] [Abstract][Full Text] [Related]
13. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV
Open Forum Infect Dis; 2016 Apr; 3(2):ofw105. PubMed ID: 27419177
[TBL] [Abstract][Full Text] [Related]
15. Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort.
Höner Zu Siederdissen C; Maasoumy B; Marra F; Deterding K; Port K; Manns MP; Cornberg M; Back D; Wedemeyer H
Clin Infect Dis; 2016 Mar; 62(5):561-7. PubMed ID: 26611779
[TBL] [Abstract][Full Text] [Related]
16. Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents.
Hong J; Wright RC; Partovi N; Yoshida EM; Hussaini T
J Clin Transl Hepatol; 2020 Sep; 8(3):322-335. PubMed ID: 33083256
[TBL] [Abstract][Full Text] [Related]
17. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1290-1300. PubMed ID: 30362139
[TBL] [Abstract][Full Text] [Related]
18. Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study.
Mangia A; Scaglione F; Toniutto P; Pirisi M; Coppola N; Di Perri G; Alvarez Nieto G; Calabrese S; Hernandez C; Perrone V; Degli Esposti L; Fagiuoli S
Int J Environ Res Public Health; 2021 Jul; 18(13):. PubMed ID: 34281080
[TBL] [Abstract][Full Text] [Related]
19. Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C.
Liu CJ; Tseng KC; Lo CC; Tseng IH; Cheng PN
J Formos Med Assoc; 2020 May; 119(5):933-940. PubMed ID: 31594667
[TBL] [Abstract][Full Text] [Related]
20. High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
Yibirin M; Hosry J; Yepez Guevara E; Granwehr BP; Jiang Y; Mustafayev K; Angelidakis G; Torres HA
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1098-1101. PubMed ID: 36062500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
